Vikram Purohit
Stock Analyst at Morgan Stanley
(0)
# 4441
Out of 5,347 analysts
207
Total ratings
28.33%
Success rate
-12.45%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
HALO Halozyme Therapeutic... | Downgrades: Equal-Weight | 73 62 | 56.07 | 10.58% | 7 | May 14, 2025 | |
ASND Ascendis Pharma | Upgrades: Overweight | 180 250 | 162.72 | 53.64% | 19 | May 5, 2025 | |
RXRX Recursion Pharmaceut... | Maintains: Equal-Weight | 10 8 | 4.17 | 91.85% | 2 | Apr 10, 2025 | |
INCY Incyte | Maintains: Equal-Weight | 69 65 | 65.01 | -0.02% | 24 | Mar 24, 2025 | |
AXSM Axsome Therapeutics | Maintains: Overweight | 125 190 | 105.16 | 80.68% | 19 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 35 | 9.51 | 268.03% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 6 9 | 4.08 | 120.59% | 9 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 31 31 | 20.96 | 47.9% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 13 6 | 2.27 | 164.32% | 7 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 7 | 2.66 | 163.16% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 7 | n/a | n/a | 16 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 15 16 | 6.03 | 165.34% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | 4.17 | 619.42% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 22 | 6.45 | 241.09% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 45 10 | 13.03 | -23.25% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 46 6 | 1.71 | 250.88% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 43 42 | 8.85 | 374.58% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 10 | n/a | n/a | 4 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 23 | 1.59 | 1315.09% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 60 30 | n/a | n/a | 6 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 3 | n/a | n/a | 2 | Jan 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 38 41 | 29.64 | 38.33% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 120 40 | 26.95 | 48.42% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 13 | 0.72 | 1705.56% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 39 38 | 21.61 | 75.84% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 24 20 | 11.38 | 75.75% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 11 10 | 9.16 | 9.17% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 18 7 | 29.59 | -76.34% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22 | 1.44 | 1427.78% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 25 60 | n/a | n/a | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 40 20 | 8.37 | 138.95% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | n/a | n/a | n/a | 2 | Mar 3, 2020 |